These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31550054)

  • 21. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of
    Blomquist KC; Nix DE
    Ann Pharmacother; 2021 Aug; 55(8):1010-1024. PubMed ID: 33228374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
    Peghin M; Maiani M; Castaldo N; Givone F; Righi E; Lechiancole A; Sartor A; Pea F; Livi U; Bassetti M
    Infection; 2018 Apr; 46(2):263-265. PubMed ID: 29086895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.
    Pybus CA; Felder-Scott C; Obuekwe V; Greenberg DE
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
    Weaver K; Stallworth K; Blakely KK
    Nurs Womens Health; 2020 Oct; 24(5):377-382. PubMed ID: 32890463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
    Simner PJ; Patel R
    J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
    Hakki M; Lewis JS
    Infection; 2018 Jun; 46(3):431-434. PubMed ID: 29460229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Pharmacology; 2018; 101(5-6):278-284. PubMed ID: 29471305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
    AlMatar M; Albarri O; Makky EA; Var I; Köksal F
    Mini Rev Med Chem; 2020; 20(18):1908-1916. PubMed ID: 32811410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
    Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.